Maximum Tolerated Dose of CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Study Title
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
Teva Identifier
C37440/1108
ClinicalTrials.gov Identifier
NCT01922752
Study Status
Completed
Trial Condition(s)
Solid Tumors
Interventions
Drug: CEP-37440

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years and older
Trial Duration
07/01/2013 - 12/01/2015
Phase
Phase 1

Study Type

Interventional